modelMethionine
Extends from Pharmacolibrary.Drugs.ATC.V.V03AB26.
Information
| name: | Methionine | |
| ATC code: | V03AB26 | route: | oral |
| compartments: | 1 | |
| dosage: | 2500 | mg |
| volume of distribution: | 0.42 | L |
| clearance: | 30 | L/h |
| other parameters in model implementation | ||
Methionine is an essential amino acid used as a nutritional supplement and an antidote for acetaminophen poisoning. It is involved in the synthesis of proteins and other important molecules and acts as a methyl group donor in various biochemical processes. The drug is approved for clinical use primarily as a nutritional supplement and as a protective agent in cases of acetaminophen toxicity.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adults, based on known amino acid pharmacokinetics and published indirect references; explicit PK data for methionine as a drug are not found in primary literature.
References
Forrest, JA, et al., & Prescott, LF (1982). Clinical pharmacokinetics of paracetamol. Clinical pharmacokinetics 7(2) 93–107. DOI:10.2165/00003088-198207020-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7039926
Shabana, S, et al., & Liu, C (2022). Multifunctional nanoparticles based on marine polysaccharides for apremilast delivery to inflammatory macrophages: Preparation, targeting ability, and uptake mechanism. International journal of biological macromolecules 222(Pt B) 1709–1722. DOI:10.1016/j.ijbiomac.2022.09.225 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36179875
Buus, S, et al., & Keiding, S (2006). Individual radiation response of parotid glands investigated by dynamic 11C-methionine PET. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 78(3) 262–269. DOI:10.1016/j.radonc.2006.02.013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16545879
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)